Temsirolimus (CCI-779) is an inhibitor of mammalian target of rapamycin (mTOR) kinase, a component of intracellular signaling pathways involved in the growth and proliferation of cells 10,11 and ...

From such efforts, temsirolimus emerged, rapidly gaining regulatory approval for the management of advanced renal cell carcinoma. Laura Boehnke Michaud News News ...

296 Background: The PI3K/mTOR/Akt pathway has been demonstrated to be active in pancreatic cancer, and preclinical data in mouse xenograft models has suggested possible synergy between gemcitabine and ...

Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor and rapamycin analogue that is approved for treating advanced renal cell carcinoma (RCC). It is being actively evaluated in ...

Temsirolimus, for the treatment of renal cancer, is now available in the U.S. from Fresenius Kabi. It is the latest addition to the company's large U.S. portfolio of generic injectable oncology ...

The objective of this study was to characterise the mechanism underlying acquired resistance to temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR), in renal cell carcinoma (RCC). A ...

Temsirolimus (formerly known as CCI-779) blocks the function of the mammalian target of rapamycin (mTOR), a key protein within cells that regulates cell proliferation, growth and survival.

June 29, 2007 (Chicago) -- Two new analyses of a phase 3 trial of temsirolimus ( Torisel, Wyeth) show the drug improves overall survival in patients with clear cell and other tumor cell types, and ...

A phase 3 trial found that temsirolimus improved overall survival in patients with advanced renal cell cancer, as compared with standard therapy with interferon alfa.

Temsirolimus produced an objective response rate of 9.2% (10 partial responses) in the intent-to-treat population. Median time to tumor progression was 12.0 weeks. Efficacy was similar for both dose ...

Oncology/Hematology > Other Cancers Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer — Adding the mTOR inhibitor didn't improve EFS in intermediate-risk rhabdomyosarcoma ...

Adventitial delivery of temsirolimus appears to safely reduce neointimal hyperplasia and target lesion failure after endovascular revascularization of below-the-knee (BTK) arteries, according to a ...